ImmuCell (ICCC) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Achieve Life Sciences is the larger company by market cap ($573.2 million vs $99.3 million), about 5.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | QUIT |
|---|---|---|
| Share price | $10.92 | $5.56 |
| Market cap | $99.28M | $573.25M |
| 1-day change | -2.41% | -5.28% |
| YTD return | +77.56% | — |
| 1-year return | +133.33% | — |
| 5-year return | +18.70% | — |
| P/E ratio (TTM) | 57.47 | — |
| EPS (TTM) | $0.19 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.64M | — |
| Revenue growth (YoY) | +4.34% | — |
| Net income (latest FY) | $-1.04M | $-54.65M |
| Gross margin | 41.40% | — |
| Operating margin | 5.97% | — |
| Net margin | -3.76% | — |
| 52-week high | $12.10 | $8.64 |
| 52-week low | $4.67 | $2.62 |
| Distance from 52-week high | -9.75% | -35.65% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +162.23% |
| Average volume | 13.44K | 1.38M |
| Shares outstanding | 9.09M | 103.10M |
| Employees | 73 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 5.8 times larger than ImmuCell by market value ($573.25M vs $99.28M).
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
ICCC vs QUIT FAQ
Which is bigger, ImmuCell or Achieve Life Sciences?
Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $99.28M for ImmuCell (ICCC).
Are ImmuCell and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.